Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.

Lung cancer (Amsterdam, Netherlands) - 1 Feb 2016

Kodityal Sandeep, Elvin Julia A, Squillace Rachel, Agarwal Nikita, Miller Vincent A, Ali Siraj M, Klempner Samuel J, Ou Sai-Hong Ignatius

Abstract excerpt

The emergence of acquired anaplastic lymphoma kinase (ALK) resistant mutations is a common molecular mechanism underpinning disease progression during crizotinib treatment of ALK-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Identifying acquired resistance mutations in ALK is paramount for tailoring future therapy with second generation ALK inhibitors and beyond. Comprehensive genomic profiling...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anaplastic Lymphoma Kinase
Share to Crizotinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Pyrazoles

Share to Pyridines

Share to Pyrimidines

Share to Receptor Protein-Tyrosine Kinases

Share to Sulfones

Source

Identifiers

PMID: 26775591
DOI: 10.1016/j.lungcan.2015.11.023

Genes

ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib.PMID 26775591Read ↗

Overcoming crizotinib resistance in ALK-rearranged NSCLC with the second-generation ALK-inhibitor ceritinib.Semantic proximity Read ↗

Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib.Semantic proximity Read ↗

Next-generation sequencing reveals a Novel NSCLC ALK F1174V mutation and confirms ALK G1202R mutation confers high-level resistance to alectinib (CH5424802/RO5424802) in ALK-rearranged NSCLC patients who progressed on crizotinib.Semantic proximity Read ↗

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer.Semantic proximity Read ↗

Identification of a Novel ALK G1123S Mutation in a Patient with ALK-rearranged Non-small-cell Lung Cancer Exhibiting Resistance to Ceritinib.Semantic proximity Read ↗

Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient.Semantic proximity Read ↗

ALK F1174V mutation confers sensitivity while ALK I1171 mutation confers resistance to alectinib. The importance of serial biopsy post progression.Semantic proximity Read ↗

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer.Semantic proximity Read ↗

Interpretation of ceritinib clinical trial results and future combination therapy strategies for ALK-rearranged NSCLC.Semantic proximity Read ↗

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Semantic proximity Read ↗

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non-small-cell lung cancer: a multicenter study using targeted next-generation sequencing.Semantic proximity Read ↗

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.